AC Immune SA
Clinical trials sponsored by AC Immune SA, explained in plain language.
AC Immune SA
ACIU
NASDAQ
Biotech developing immunotherapies for neurodegenerative diseases like Alzheimer's.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new PET tracer light up the protein behind some dementias and ALS? Results expected Nov 2026 (estimated)
- New brain drug ACI-19764 enters first human safety tests Results expected Dec 2026 (estimated)